Comprehensive Study Guide to Pediatric Non-bacterial and Bacterial Pneumonias

General Characteristics and Etiology of Non-bacterial Atypical Pneumonias

Non-bacterial or atypical pneumonias represent a cluster of community-acquired pulmonary disorders caused by non-bacterial agents. These conditions are clinically identified by a moderate fever, cough, and tachypnea, with the latter being particularly significant in very young children. A defining feature of these infections is the discrepancy between the severe radiological findings and the relatively poor or even normal physical examination of the lungs. Radiologically, these pneumonias manifest as an accentuated bronchovascular pattern with thickened hila, signifying an underlying involvement of the pulmonary interstitium. Consequently, many clinicians refer to this condition as acute interstitial pneumonia. While the infectious syndrome is generally less grave than that of bacterial pneumonias, clear differential diagnosis is not always possible. Atypical pneumonia is defined pathologically as an acute inflammatory process resulting in the infiltration of the pulmonary interstitium with inflammatory cells, which may or may not be accompanied by alveolitis. Inflammatory exudate is also observed within both the large and small bronchi.

Viruses are identified as the most prominent non-bacterial etiological agents in this category. All viruses with respiratory tropism can act as determining factors for interstitial pneumonia. The most frequent agents include the respiratory syncytial virus ($VSR$), influenza and parainfluenza viruses, metapneumovirus, adenoviruses, rhinoviruses, and cytomegalovirus ($CMV$). Among non-viral atypical agents, Mycoplasma pneumoniae and species from the Chlamydia genus are highly significant. Identifying these microorganisms is technologically demanding and requires specialized laboratory settings. Viruses isolated from children with atypical pneumonia are considered highly probable etiological agents, as they are rarely identified in similarly tested control groups.

Pathophysiology and the Histological Structure of the Alveolar-Interstitial Space

Understanding the mechanism of atypical pneumonias requires a detailed review of the lung's histological elements, particularly the alveoli which are arranged in clusters around the bronchioles. Each alveolus possesses a wall consisting of a single epithelial layer situated on a basement membrane, a structure that bears a remarkable analogy to the renal glomerulus. The alveolar epithelium is composed primarily of type I alveolar cells, making up $95\%$ of the surface, and cuboidal type II alveolar cells, which account for the remaining $5\%$. The type II cells are vital for the synthesis of surfactant, the most important surface-active substance that prevents alveolar collapse. Opposing the alveolar epithelium is the pulmonary interstitium, a region characterized by a connective tissue matrix containing collagen, elastic fibers, proteoglycans, and glycoproteins. The pulmonary capillaries, which have their own endothelium and basement membrane, reside within this interstitial space. In specific areas, the alveolar epithelium and capillary endothelium come into direct contact to facilitate gas exchange.

In a healthy lung, the alveolar wall is extremely thin, measuring between $5-10\,\mu$, while the alveolar space is significantly larger at $200-300\,\mu$. The normal interstitium contains approximately $80$ inflammatory cells per alveolus, $90\%$ of which are alveolar macrophages, while the rest are phagocytic cells derived from blood monocytes, such as T and B lymphocytes. Importantly, polymorphonuclear cells are absent in a healthy lung, and the existing cells remain inactive. In contrast, interstitial pneumonias are characterized by the accumulation of inflammatory cells in the interstitium that become activated by the etiological agent. This cellular influx and the resulting edema can cause the pulmonary interstitium to thicken by $2-4\times$, inevitably disturbing gas exchange and leading to hypoxia. This process is often accompanied by diffuse alveolar damage, involving the necrosis of type I cells, the proliferation of type II cells, the presence of alveolar exudate, and the formation of hyaline membranes, although the basement membrane typically remains intact.

Clinical Pathogenesis and Histological Variants of Viral Infection

Unlike non-infectious interstitial lung diseases which are often progressive and lead to chronic, irreversible respiratory failure, the inflammatory process in infectious atypical pneumonia is generally reversible. However, specific agents like adenovirus type 3 can cause long-term, progressive lung damage. Histologically, viral pneumonias present two distinct variants of damage. The first variant, characteristic of $VSR$ infection, involves the ciliary epithelium of the bronchi and bronchioles becoming cuboidal or flat and losing its cilia, which severely impairs mucociliary clearance. In these cases, the subepithelial tissue and interalveolar walls become heavily infiltrated with mononuclear cells and significantly thickened. The second variant, typical of adenovirus or parainfluenza infections, involves more severe lesions in the bronchiolar walls and alveoli. This type is marked by necrosis of alveolar and bronchial epithelial cells and the presence of intranuclear inclusions. The alveolar epithelium may be replaced by a stratified, undifferentiated epithelium, and some alveoli are lined with thick hyaline membranes. The interstitium and bronchiolar walls in this variant contain an inflammatory infiltrate composed of macrophages, plasma cells, and lymphocytes.

Clinical signs of atypical pneumonia are often shared with other lower respiratory tract infections. Fever is absent in $92\%$ of cases or remains at moderate levels. The pulmonary condition is frequently preceded by an upper respiratory tract infection, characterized by coryza, nasal obstruction, malaise, and anorexia. The full clinical picture usually develops within $2-3$ days, presenting as cough and chest pain in older children, or cough and tachypnea in younger ages. Infants in the first six months of life may develop acute respiratory failure with tachypnea exceeding $40\,\text{breaths/min}$, nasal flaring, perioronasal cyanosis, and suprasternal or inferior intercostal retractions. Physical signs are often sparse, limited to breath sounds, bronchial rales, or rhonchi, which frequently do not correlate with the severity of radiological findings. Specific etiological clues include convulsions at the onset of influenza pneumonia, gastrointestinal disturbances and consciousness alterations in adenovirus infections, and a characteristic rash in Mycoplasma pneumoniae infections.

Diagnostic Procedures and Laboratory Evaluations

Chest radiography is the only paraclinical examination besides virological testing that is truly useful for supporting a diagnosis of atypical pneumonia. The characteristic appearance consists of visible thickening of the bronchovascular pattern, an accentuated interstitium, and diffuse infiltrates. Ventilation disturbances, such as zones of hyperlucency or segmental atelectasis, are often present. While the radiological image resembles bronchiolitis, the degree of hyperinflation is usually less pronounced. Serological tests can demonstrate increased specific $IgG$ and $IgM$, and cold agglutinins are specifically noted in Mycoplasma cases. Basic evaluation involves checking the blood count, acute phase reactants, and peripheral oxygen concentration via pulse oximetry, which are usually sufficient for management. The severity of the clinical picture is most remarkable in small infants or those with biological handicaps like advanced dystrophy or congenital heart disease.

Distinct Clinical Forms: Chlamydia, CMV, and Mycoplasma

Chlamydia pneumonia in small infants occurs when $5-20\%$ of mothers with genital Chlamydia infections transmit the pathogen during labor. Roughly $35\%$ of these infants develop conjunctivitis, and $20\%$ develop pneumonia, typically starting between $3-6$ weeks of age. A suggestive clinical sign is conjunctivitis that is resistant to classic therapy. The infant is usually afebrile but becomes progressively tachypneic with paroxysmal cough crises resembling pertussis, sometimes accompanied by perioronasal cyanosis or apnea. Radiography shows diffuse infiltrates, and laboratory tests reveal hyper $IgM$ and hyper $IgG$ levels that are $2-4\times$ higher than normal, along with hypereosinophilia exceeding $400/mm^{3}$. Diagnosis is confirmed by demonstrating Chlamydia inclusions in alveoli via lung biopsy. Prevention relies on treating the mother before labor.

Cytomegalovirus ($CMV$) pneumonia is a particular entity in small infants, transmitted transplacentally from seropositive mothers. While roughly $90\%$ of cases are asymptomatic, perinatal infections can manifest as acute interstitial pneumonia after an incubation period of $6-8$ weeks. Clinical signs include a frequent, spastic, repetitive cough and radiological peribronchial infiltrates with moderate hyperaeration. Hemograms show leukocytosis between $14,000-19,000/mm^{3}$ with sterile bacterial cultures. The condition often has a lingering course that can progress toward chronic respiratory failure. Diagnosis is difficult and relies on showing $CMV$ in blood or urine, specific antibodies, or the classic "owl's eye" intranuclear inclusions in alveolar cells detected via biopsy.

Mycoplasma pneumoniae pneumonia is rare under the age of $4-5$ years, with peak incidence between $5-15$ years. It starts after a $3$-week incubation with fever, headache, and sore throat. The initial unproductive cough becomes paroxysmal and may eventually produce blood-streaked sputum. A major systemic association is the presence of a rash in $11\%$ of cases, which can be maculoerythematous, vesicular, bullous, or urticarial, lasting $7-14$ days. Other systemic involvements include pericarditis, myocarditis, and arthritis. Differential diagnosis includes atypical measles or Kawasaki disease if fever and rash are severe.

Positive and Differential Diagnosis of Non-bacterial Pneumonias

The positive diagnosis of non-bacterial pneumonia is based on the combination of fever, cough, tachypnea (in infants) or chest pain (in older children), typical radiological changes, and minimal physical findings. Specific etiology can be confirmed through virus isolation from nasopharyngeal swabs, viral antigen detection, or complement fixation ($RFC$) to identify specific antibodies. Acute phase reactants like C-reactive protein ($CRP$) typically show low values, averaging $2.5 \pm 1.9\,mg/dl$, compared to the higher levels in bacterial pneumonias ($5.7 \pm 6.1\,mg/dl$). A negative acute phase reactant status is highly characteristic of atypical pneumonia. Differential diagnosis must distinguish lower respiratory tract infections from upper tract infections, and distinguish between viral and bacterial causes, the latter being one of the most difficult challenges in pediatric practice. No single clinical or laboratory criterion is absolute. Evidence suggests that $15\%$ of children who have had non-bacterial pneumonia maintain persistent radiological images for $1-5$ years, and early childhood pneumonias may predispose individuals to increased pulmonary morbidity in adulthood.

Prophylactic and Medical Treatment of Atypical Pneumonias

Treatment for non-bacterial pneumonia partially overlaps with that for bronchiolitis, though bronchodilators are not indicated without wheezing. Antibiotics generally do not benefit viral pneumonias or prevent bacterial superinfection. However, empirical antibiotics are recommended for febrile or dystrophic infants in their first trimester of life, or if general signs suggest bacterial involvement (rising fever, productive cough, or positive acute phase reactants). Initial empirical therapy often involves ampicillin at $100-200\,mg/kg/day$ combined with gentamicin at $5-7\,mg/kg/day$. Mycoplasma infections respond to erythromycin propionate ($30-50\,mg/kg/day$), clarithromycin ($15\,mg/kg/day$), or doxycycline ($4\,mg/kg$ on day 1, then $2\,mg/kg$). Chlamydia trachomatis requires erythromycin at $40\,mg/kg$ or clarithromycin for a prolonged period of $3-4$ weeks. For severe viral cases, amantadine ($4.4-8.8\,mg/kg$ for children ages $1-9$, max $150\,mg/day$) or ribavirin (delivered via aerosol $12-18\,hours/day$ for $3-7$ days) may be used. Supportive care includes antipyretics like acetaminophen or aspirin at $10\,mg/kg$ per dose, although aspirin must not exceed $1.4\,g/day$ in older children.

Bacterial Pneumonias and Diagnostic Scoring Systems

Bacterial pneumonias result from bacterial infection of the lung parenchyma, leading to inflammatory cell infiltration of the interstitium and intra-alveolar exudate. Agents like staphylococcus and gram-negative bacteria can cause parenchymal necrosis followed by lung abscesses. Diagnosis is often based on clinical and radiological findings, but establishing the specific etiology is difficult. A pediatric radiological scoring system (Table 9.3) aids diagnosis: well-defined lobar or segmental infiltrates score $+2$, while poorly defined spots or peribronchial interstitial patterns score $+1$ or $-1$. Pleural effusion or abscesses score $+2$. A diagnostic score for bacterial pneumonia (Table 9.4) combines these with laboratory data: leukocytosis ($>20,000\,mm^{-3}$), absolute PMN count ($>10,000\,mm^{-3}$), left shift ($>500\,mm^{-3}$ immature cells), temperature over $39\,^{\circ}C$, and $CRP > 20\,mg/dl$. A score $> 1$ suggests bacterial infection, whereas viral pneumonia scores between $1.5-3$, pneumococcal pneumonia averages $4.4$, and staphylococcal pneumonia matches $6.5$.

Pneumococcal Pneumonia: Biology and Epidemiology

Pneumococcal pneumonia is caused by Streptococcus pneumoniae, previously known as Diplococcus pneumoniae. Historically, it was the most common etiological agent in $90\%$ of childhood pneumonias, though incidence has dropped significantly with conjugate vaccines. The bacterium is a Gram-positive, encapsulated, lanceolate diplococcus. The polysaccharide capsule provides type specificity and prevents phagocytosis. Type-specific capsular antibodies are protective. Epidemiology shows infections are more common in cold seasons (October to March). While the bacterium can be found in healthy carriers, this plays a minor role in dissemination. The maximum incidence occurs between $6$ months and $4$ years of age.

Pathogenesis and Clinical Evolution of S. pneumoniae

Pneumococcal pneumonia typically occurs when local respiratory defenses fail, often following a viral infection that increases mucus and impairs ciliary activity. Alveolar edema serves as a culture medium for the cocci. The infection spreads centrifugally through the pores of Kohn and terminal bronchioles. The histological process involves stages: red hepatization, marked by edema and intra-alveolar hemorrhage where the lung becomes hard and liver-like in consistency, followed by gray hepatization, where PMNs and macrophages invade to initiate phagocytosis. Resolution occurs as macrophages replace PMNs. While the process usually affects a segment or lobe, small infants often present disseminated broncho-alveolitis, historically called bronchopneumonia. Complete healing is typical and tissue necrosis is rare except in type 3 infections.

Clinical onset in older children is traditionally described by a triad: hyperthermia, cough, and thoracic pain. Infants present more non-specific signs, such as a sudden fever rise above $39\,^{\circ}C$, irritability, and respiratory distress. Signs include expiratory grunting, polypnea ($>60\,\text{breaths/min}$), nasal flaring, and "piston" movements of the head. Physical examination might reveal sub-dullness or dullness over consolidation zones, decreased breath sounds, and fine alveolar rales. A characteristic tubular breath sound occurs if consolidation is extensive. Abdominal distension (toxic meteorism) can imitate an acute abdomen, and right upper lobe involvement may cause neck rigidity without meningitis.

Diagnostic Features and Complications of Pneumococcal Infection

Laboratory tests consistently show leukocytosis ($>20,000\,mm^{-3}$) with neutrophilia ($75-80\%$) and a left shift. $VSH$ (erythrocyte sedimentation rate) often exceeds $50\,mm/h$, and $CRP$ values over $20\,mg/l$ confirm the bacterial etiology. Leukopenia below $5,000/mm^{3}$ is a grave prognostic sign. Blood cultures are positive in $20-30\%$ of cases. Radiography usually reveals a triangular unilateral opacity with costal intensity, most often in the right middle or superior lobes. Capsular polysaccharide can be detected in blood, sputum, or urine using counterimmunoelectrophoresis or latex agglutination. Specific complications include pleural effusion (empyema in $2-3\%$), pneumococcal meningitis (grave prognosis with $15\%$ mortality and high neurological sequelae), and pericarditis. Peritonitis may occur, especially in patients with nephrotic syndrome.

Medical Management of Pneumococcal Pneumonia

Penicillin remains the shock antibiotic of choice for S. pneumoniae. It should be initiated promptly to limit local and hematogenous spread. The recommended dose is $300,000-400,000\,UI$ every $6$ hours, given intramuscularly or via intravenous infusion for $7-10$ days. Clinical response is usually spectacular within $48$ hours. Alternatives for penicillin-allergic patients include erythromycin, clarithromycin, or first-generation cephalosporins at $50\,mg/kg$. Supportive care, including hydration and oxygen therapy, is vital, especially for infants. If no response is seen after penicillin, clinicians should suspect complications (empyema, abscess) or a different agent (staphylococcus). Prevention is achieved through polyvalent polysaccharide vaccines (Pneumo 23) for high-risk groups or conjugate vaccines for all infants.

Staphylococcal Pneumonia: Pathophysiology and Bacteriology

Pneumonia caused by Staphylococcus aureus is a severe, rapidly progressive disease with mortality exceeding $10\%$. It is most common in infants and can be community-acquired or nosocomial. Methicillin-resistant S. aureus ($MRSA$) is a significant concern. The bacterium is a Gram-positive coccus that appears in clusters. It resists $β$-lactams through enzymatic degradation. Pathogenic strains produce various toxins, including enterotoxin, epidermolytic toxin, and leucocidin, which inactivates phagocytes. Protein A prevents antibodies from acting as opsonins. S. aureus has a specific tendency to form abscesses and induce suppuration. Lung involvement usually follows a viral infection and is typically unilateral. Necrosis involves lung elastic tissue, leading to the characteristic development of pneumatoceles (bullae), which can grow due to mechanical forces and ruptured septa.

Clinical Stages and Manifestations of Staphylococcal Infection

The disease often begins brutally with high fever, cough, and rapid onset of major acute respiratory failure. The infant appears "toxic," anxious, and lethargic. Gastrointestinal signs like toxic meteorism and vomiting are common. Three clinical-radiological stages are described. The initial stage mimics viral pneumonia but with a toxic general appearance. The abscessed stage presents as massive bronchopneumonia with confluent abscesses. The stage of massive pleurisy involves leather-like dullness of the hemithorax and may progress to pyopneumothorax in $60-70\%$ of cases. A tension (valve) pneumothorax causes sudden clinical worsening. Pneumatoceles appear after day $12$ and may persist for weeks or years, often resolving through progressive concentric erasure. Septicemic forms occur in $25\%$ of cases, with bilateral abscesses and extrapulmonary foci like osteomyelitis ($32\%$ in infants).

Diagnosis and Treatment of Staphylococcal Pneumonia

Radiology is the definitive diagnostic tool, showing unilateral lesions (typically right-sided) that evolve rapidly from infiltrates to pleurisy or pneumatoceles. Laboratory tests show anemia, leukocytosis ($>20,000/mm^{3}$) with neutrophilia ($75-85\%$), and high $CRP$ and $VSH$ ($>50\,mm/h$). Pleural fluid analysis shows an exudate with high PMNs ($>1,000/mm^{3}$, often up to $100,000/mm^{3}$) and $pH < 7.3$. Treatment requires aggressive antibiotics and drainage of purulent collections. Vancomycin is the primary choice, dosed at $15-20\,mg/kg$ every $6$ hours (target serum levels $15-20\,\mu g/ml$). Alternatives include Linezolid ($600\,mg$ twice daily for those $>12$ years) or Clindamycin ($40\,mg/kg/day$). Surgical intervention often involves placing a Pezzer probe or a Beclair drain system for continuous passive drainage. Re-expansion of the lung is monitored for up to six weeks.

Opportunistic Infections: Pneumocystis jiroveci

Pneumocystis jiroveci (formerly P. carinii) causes a progressively dyspneic pneumopathy in immunocompromised hosts, such as premature infants, malnourished children, or those with $HIV$ ($42\%$ frequency in SIDA stage P2D2). The agent is a saprophytic fungus. It has three evolutionary stages: vegetative (trophozoite), pre-cystic, and cyst. Infections in Romanian orphanages were noted in the $1980$s among malnourished infants. Risk factors include CD4 counts below $1,500/mm^{3}$ in those under one year. Clinical signs include an insidious onset, "slate-like" cyanosis, and a remarkably high respiratory rate ($80-100\,\text{breaths/min}$). Radiographically, it shows a "ground glass" ($“geam mat”$) appearance with perihilar opacities that spread peripherally. Diagnosis is made through silver stains like Gomori-Grocott or Gram-Weigert on bronchial lavage fluid.

Treatment of Pneumocystis involves Pentamidine isothionate at $3-4\,mg/kg/day$ intramuscularly for $10-14$ days, or Trimethoprim-Sulfamethoxazole ($TMP-SMX$) at high doses: $15-20\,mg/kg/day$ of $TMP$ or $75-100\,mg/kg/day$ of $SMX$. Prophylaxis for high-risk $HIV$ patients involves $TMP-SMX$ at $150\,mg/m^{2}$ three times weekly. Without treatment, mortality is near $100\%$, but decreases to $30-50\%$ with specific therapy. Recovery is slow, occurring over $2-8$ weeks. Adjuvant intravenous immunoglobulin and corticosteroids may improve survival rates by reducing the inflammatory response.